ProbioTech USA Revenue

About ProbioTech USA

ProbioTech USA is pioneering a new frontier in prescription Live Biotherapeutic Products (LBPs), uniquely combining beneficial bacteria with antioxidants to enhance potency against infections and inflammation. With safety profiles informed by millions of daily probiotic exposures in food and supplements, we translate real-world evidence into a robust pipeline of prescription-only therapeutics, administered via oral, rectal, or vaginal delivery. Our patented dual-phase delivery technology ensures precise, site-specific release of active ingredients, manufactured to pharmaceutical-grade standards. Unlike donor-derived microbiota, our cultured bacteria meet rigorous quality control requirements and are developed with a clear purpose: to modulate the human microbiome and treat a range of chronic and infectious conditions. ProbioTech USA has Innovation and Change ingrained in our DNA Team • Deborah Lu Lynch, BA, MBA – President, Founder & CEO • Brinda Wiita, PhD, MBA – Chief Scientific Officer • Emilia Lonardo, MT (ASCP), PhD – Vice President, Regulatory • James Barr, JD – Counsel • Justin Crotty, JD, PhD – Saul Ewing • Andrew Bosco – Dunn Regulatory • Alastair Southwell – Alacrita • Lucas Rodriguez – Alacrita • Luc Poppe – Sentosa Partners Advisors • Sahil Khanna, MBBS, MS, FACG, AGAF – Mayo Clinic • Paul Feuerstadt, MD, FACG, AGAF – Yale University • William Tremaine, MD – Mayo Clinic (Emeritus) • Robert Britton, PhD – Baylor College of Medicine • Jonca Bull, MD • Johna Lucas, MD, FACOG • Jane Schwebke, MD, FACP, FIDSA – University of Alabama (Emerita)

View contact profiles from ProbioTech USA